• The negotiation period is between 9th until 15th June, both inclusive
  • The purpose is to finance the Group’s growth through the acquisition of a pharmaceutical laboratory, increasing the integration in the value chain as well as its services portfolio to third parties and the number of international clients.

Jerez, June 9th 2015. The Board of Directors of Bolsas y Mercados Españoles (BME) has agreed the listing from today Tuesday and until next Monday, June 15th, both inclusive, 4.633.036 preferential subscription rights of the Bionaturis Group that will be negotiated in the Alternative Equity Market (MAB) under the code (BNT.D).

The rights negotiation of the new Bionaturis shares falls within the subscription period, which is scheduled4th July to be over. Once completed it and if there is any shares left, discretionary assignment period will be open to place the remaining shares to other investors.

This capital increase, approved last week by the governing body of the MAB, aims to stimulate the Company’s growth process by financing the acquisition of the entire capital share of a laboratory that manufactures exclusively to third parties (Contract Manufacturing Organization).

The capital increase, that retains the preferential subscription right, involves the issue of a maximum of up to 579,129 new shares, with the same class and rights, with a par value of €0,05 per share, and a share premium of €6,95 per share. Furthermore, it was agreed to offer the new shares at a ratio of 1 new share for every eight old, free of issue expenses.

Currently the Company has a share capital of €231,651,8 consisting of 4,633,036 shares with a par value of €0,05 per share. If the increase fully subscribes, the final share capital will be €260,608,25, divided amongst 5,212,165 shares with a par value of €0,05 each one.

The new issued shares will trade in MAB as soon as possible once the registration, compensation and liquidation value system (Iberclear) have been registered, after closing the negotiation of the preferential subscription rights and discretionary assignment periods and, therefore, of the ending of the current capital increase.

About Bionaturis Group

The Bionaturis Group offers cutting-edge biotechnological products and services for human and animal health. Considered an international benchmark in the vaccines research, Bionaturis Group closed last exercise with an increase of sales of 73% and a positive EBITDA of 29% compared to the previous year. The biotechnological Group which envisages a global access to health, is listed on the Spanish Stock Exchange for SMEs (ticker BNT).